Document Detail

A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
MedLine Citation:
PMID:  12736713     Owner:  NLM     Status:  MEDLINE    
One of the major side effects of ribavirin/interferon alpha combination therapy for chronic hepatitis C is hemolytic anemia. One of the causes of hemolytic anemia is considered to be decreasing deformability of erythrocytes resulting from the accumulation of phosphorylated ribavirin in erythrocytes. The administration of eicosapentaenoic acid (EPA), which has a wide variety of pharmacological actions, increases the deformability of erythrocytes. We conducted an uncontrolled pilot study of EPA therapy for patients with ribavirin-related anemia. Six patients with chronic hepatitis C, who had developed anemia while receiving combination therapy, were treated with an oral ethyl ester of EPA (1800 mg/day) for two months. The hemoglobin level of all six patients increased following EPA therapy. The mean hemoglobin level significantly increased from 10.8 g/dl to 11.4 g/dl one month after therapy was initiated (P<0.05), and this level was obtained again one month later (11.5 g/dl). None of the patients developed an adverse reaction. These findings suggest that EPA has a beneficial effect in patients with ribavirin-related anemia. Further study is required to confirm our results.
Tatsuya Ide; Takashi Okamura; Ryukichi Kumashiro; Yuriko Koga; Teruko Hino; Akiko Hisamochi; Kei Ogata; Kazuo Tanaka; Reiichiro Kuwahara; Ritsuko Seki; Michio Sata
Related Documents :
471423 - A possible association of pernicious anemia with neoplasia.
16037973 - Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome.
4045953 - The inheritance of primary lymphoedema.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of molecular medicine     Volume:  11     ISSN:  1107-3756     ISO Abbreviation:  Int. J. Mol. Med.     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-05-08     Completed Date:  2004-02-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9810955     Medline TA:  Int J Mol Med     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  729-32     Citation Subset:  IM    
Second Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / blood,  chemically induced*,  drug therapy*
Antiviral Agents / adverse effects*
Eicosapentaenoic Acid / therapeutic use*
Hemoglobins / metabolism
Hepatitis C, Chronic / drug therapy*
Interferon Alfa-2b / adverse effects
Middle Aged
Pilot Projects
Reticulocyte Count
Ribavirin / adverse effects*
Reg. No./Substance:
0/Antiviral Agents; 0/Hemoglobins; 1553-41-9/Eicosapentaenoic Acid; 36791-04-5/Ribavirin; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Late-onset obesity in mice transgenic for the human renin gene.
Next Document:  Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma sy...